ZYBRESTAT

Related by string. Zybrestat * * ZYBRESTAT selectively targets . solid tumors ZYBRESTAT . ZYBRESTAT TM . ZYBRESTAT fosbretabulin *

Related by context. All words. (Click for frequent words.) 72 phase IIb clinical 71 phase IIa clinical 70 CR# vcMMAE 70 sapacitabine 70 forodesine 69 INCB# [001] 69 oral ridaforolimus 69 PEG SN# 69 axitinib 69 OXi# 69 Zybrestat 68 ganetespib 68 talactoferrin 68 obatoclax 67 pomalidomide 67 romidepsin 67 alvespimycin 67 tanespimycin 67 PXD# 67 rNAPc2 67 metastatic castration resistant 67 Triolex 67 fosbretabulin 66 vidofludimus 66 Phase 1b trial 66 CA4P 66 picoplatin 66 brivaracetam 66 CoFactor 66 radiation sensitizer 66 vandetanib 66 Phase 2a trial 66 TG# [003] 66 HGS ETR1 66 HuMax EGFr 66 Ophena TM 66 Cloretazine R VNP#M 66 BRIM2 66 Azedra 66 Tarceva TM 66 Tezampanel 65 Archexin 65 ZYBRESTAT TM 65 tesmilifene 65 PDE4 inhibitor 65 KRN# 65 Targretin 65 Zerenex 65 Voreloxin 65 Phase Ib study 65 Azixa 65 pan HDAC inhibitor 65 ponatinib 65 EOquin TM 65 eltrombopag 65 pralatrexate 65 OncoVEX GM CSF 65 DU #b 65 RSR# 65 Phase IIa clinical 65 vascular disrupting agent 65 CYT# potent vascular disrupting 65 plus gemcitabine 65 AP# [003] 65 Phase 2a clinical 65 JAK inhibitor 65 cutaneous T cell 65 IRX 2 65 teriflunomide 65 Amrubicin 65 PRT# 65 LibiGel ® 65 Carfilzomib 65 SCH # 65 YONDELIS 65 Phase Ib clinical 65 mapatumumab 64 PEG Interferon lambda 64 metastatic renal cell carcinoma 64 phase IIb 64 recurrent glioblastoma 64 FOLOTYN ® 64 L BLP# 64 Xanafide 64 microplasmin 64 glufosfamide 64 Imprime PGG 64 ZOLINZA 64 GAMMAGARD 64 CEQ# 64 CYT# 64 CCX# B 64 CIMZIA TM certolizumab pegol 64 Phenoptin 64 evaluating tivozanib 64 Phase IIIb clinical 64 TELINTRA 64 CRx 64 neratinib 64 lymphoma CTCL 64 Pivotal Phase III 64 perifosine 64 metastatic hormone refractory 64 sunitinib malate 64 Romidepsin 64 LymphoStat B 64 enzastaurin 64 Phase 2b study 64 oral prodrug 64 Golimumab 64 Laquinimod 64 IMA# 64 Panzem 64 Bezielle 64 tezampanel 64 phase IIa 64 phase IIb trial 64 ISIS # 64 Ceflatonin 64 celgosivir 64 AEG# 64 HuLuc# 64 ELACYT 64 Cotara 64 Pivotal Phase 64 ZYBRESTAT fosbretabulin 64 TELCYTA 64 NGX# 64 pertuzumab 64 elotuzumab 64 OvaRex ® MAb 64 cilengitide 64 MAGE A3 ASCI 64 Bicifadine 64 Phase #/#a trial 64 Sapacitabine 64 OPAXIO 64 Panzem R NCD 63 Phase IIb trials 63 recurrent GBM 63 FOLOTYN 63 PRTX 63 riociguat 63 Dacogen injection 63 MAP# 63 IL# PE#QQR 63 Treanda 63 velafermin belinostat 63 OMNARIS HFA 63 GLYX 63 IMGN# 63 MAXY G# 63 XYOTAX TM 63 cutaneous T 63 Seliciclib 63 tolerability profile 63 zalutumumab 63 Phase #b/#a clinical 63 SinuNase 63 subcutaneous formulation 63 CRMD# 63 Traficet EN 63 MERLIN TIMI 63 ADVEXIN 63 Iluvien ® 63 BAY #-# 63 Diabetic Macular Edema 63 EFAPROXYN 63 Phase Ib II 63 metaglidasen 63 Allovectin 7 63 sorafenib tablets 63 Tyrima 63 lintuzumab SGN 63 confirmatory Phase III 63 registrational 63 Phase Ib 63 sorafenib Nexavar 63 Phase 1b clinical 63 Symadex 63 vemurafenib 63 custirsen 63 Aflibercept 63 generation purine nucleoside 63 Cimzia TM 63 TLK# 63 ongoing Phase 1b 63 alvimopan 63 R#/MEM # 63 Phase III clinical 63 laquinimod 63 INCB# [002] 63 Phase 2b clinical 63 Pivotal Trial 63 recurrent glioblastoma multiforme 63 oral salmon calcitonin 63 Phase 2b Clinical Trial 63 eniluracil 63 CCX# 63 registrational trial 63 Glufosfamide 63 liposomal formulation 63 RDEA# 63 Asentar 63 Tamibarotene 63 dimebon 63 HQK 63 Panzem R 63 BRAF inhibitor 63 CIMZIA TM 63 omega interferon 63 crizotinib PF # 63 PRECISE trial 63 Microplasmin 63 volociximab 63 Nexavar ® 63 HGS# 63 Phase 2b trial 63 LEUKINE 63 XL# [003] 63 eculizumab 62 AVONEX ® 62 EOquin 62 double blinded placebo 62 EGS# 62 torezolid phosphate 62 Phase 2a 62 Hsp# Inhibitor 62 OvaRex R 62 mertansine 62 Daclizumab 62 Reverset 62 elacytarabine 62 teduglutide 62 Phase IIa trial 62 randomized Phase 2b 62 lintuzumab 62 Zenvia ™ 62 metastatic castrate resistant 62 iSONEP 62 relapsed multiple myeloma 62 RLY# 62 MAA submission 62 PCK# 62 thymalfasin 62 diabetic neuropathic pain 62 Campath ® 62 Nasulin 62 veltuzumab 62 CDP# 62 MOZOBIL 62 phase IIb study 62 Trofex TM 62 trastuzumab Herceptin R 62 PS# [001] 62 anti leukemic 62 Phase IIb clinical 62 ILUVIEN ® 62 docetaxel Taxotere ® 62 PREZISTA r 62 XmAb# 62 Marqibo 62 Tanespimycin 62 Entereg R 62 maximally tolerated dose 62 ENDEAVOR IV 62 T DM1 62 novel VDA molecule 62 cell lymphoma CTCL 62 ACTEMRA TM 62 Troxatyl 62 HuMax CD4 62 APEX PD 62 Mipomersen 62 acetonide FA 62 Viramidine 62 Cloretazine ® 62 Phase 1b 62 phase Ib 62 novel oral anticoagulant 62 PDX pralatrexate 62 Irinotecan 62 docetaxel Taxotere R 62 Pralatrexate 62 lorvotuzumab mertansine 62 amrubicin 62 Pafuramidine 62 CINTREDEKIN BESUDOTOX 62 ixabepilone 62 bendamustine 62 relapsing remitting multiple sclerosis 62 mTOR inhibitor 62 Zenvia Phase III 62 RSD# oral 62 GRN# 62 Plicera 62 BRIM3 62 EVIZON 62 posaconazole 62 vicriviroc 62 Onrigin 62 Tesetaxel 62 MYDICAR ® 62 Aurexis 62 nab paclitaxel 62 LY# [003] 62 Bortezomib 62 omacetaxine mepesuccinate 62 Hedgehog Pathway Inhibitor 62 HCD# [002] 62 peginesatide 62 ospemifene 62 virus HCV protease inhibitor 62 Phase #b/#a 62 pharmacokinetic PK 62 Atiprimod 62 EDEMA3 62 BCX# 62 multi kinase inhibitor 62 ILLUMINATE 62 Dasatinib 62 castrate resistant prostate cancer 62 Fludara 62 HGS ETR2 62 phase 2a 62 CYC# 62 Myocet 62 regorafenib 62 Albuferon TM 62 Anturol TM 62 tecarfarin 62 PROSTVAC TM 61 cetuximab Erbitux 61 HSP# inhibitor 61 Chemophase 61 CYCLOSET 61 vascular disrupting agents 61 belinostat 61 dextromethorphan quinidine 61 tezampanel NGX# 61 Evoltra 61 unresectable stage 61 oral Xeloda 61 Darusentan 61 dirucotide 61 refractory gout 61 Talactoferrin 61 Stedivaze 61 voreloxin 61 paclitaxel Taxol ® 61 Clolar ® 61 lumiliximab 61 bardoxolone methyl 61 interferon gamma 1b 61 oral FTY# 61 PD LID 61 Vernakalant 61 PROMACTA 61 Phase #/#a 61 PEP# [003] 61 Phase IIB 61 cediranib 61 samalizumab 61 bevacizumab Avastin ® 61 ALKS 61 Sphingomab 61 mRCC 61 capecitabine Xeloda R 61 Capesaris 61 aflibercept 61 CBLC# 61 Initiate Phase 61 elvucitabine 61 multicenter Phase II 61 trastuzumab DM1 T DM1 61 TORISEL 61 MGd 61 TRIOLEX 61 CIMZIA ™ 61 pharmacodynamic properties 61 Apoptone 61 Phase III Pivotal 61 cangrelor 61 PI3K/Akt pathway inhibitor 61 Alocrest 61 entinostat 61 Randomized Phase 61 relapsed refractory multiple myeloma 61 TOCOSOL Paclitaxel 61 IIa trial 61 CRLX# 61 ZACTIMA 61 Tavocept 61 randomized controlled Phase 61 seliciclib 61 refractory acute myeloid 61 APTIVUS 61 HuMax CD# 61 Proxinium TM 61 zanolimumab 61 Relivar 61 PANVAC VF 61 refractory chronic lymphocytic 61 Zevalin R Ibritumomab 61 Phase IIb Trial 61 ataluren 61 unique alkylating agent 61 #ME# 61 delivers fluocinolone acetonide FA 61 cabazitaxel 61 IRESSA 61 Ambrisentan 61 Elagolix 61 TTF Therapy 61 Serdaxin 61 Talabostat 61 Neurodex 61 monotherapy 61 decitabine 61 Phase IIb clinical trials 61 HER2 positive metastatic breast 61 ASONEP 61 oral methylnaltrexone 61 TBC# 61 mTOR inhibitors 61 ProSavin 61 Allovectin 7 R 61 GSK# [001] 61 oral picoplatin 61 rhThrombin 61 Virulizin ® 61 PEGylated interferon beta 1a 61 Apixaban 61 Personalized Immunotherapy 61 Meets Primary Endpoint 61 satraplatin 61 RG# [001] 61 ruboxistaurin 61 erlotinib Tarceva ® 61 NOX E# 61 orally bioavailable 61 Sym# 61 OMS# 61 Cethromycin 61 PSN# [002] 61 mitogen activated ERK kinase 61 atacicept 61 Reolysin 61 Elotuzumab 61 anticancer compound 61 Genz # 61 aclidinium 61 PNP inhibitor 61 Fx #A 61 trabedersen 61 AZILECT R 61 adecatumumab 61 PRX # 61 pivotal Phase III 61 nitazoxanide 61 ISTODAX 61 placebo controlled Phase 61 huC# DM4 61 trodusquemine 61 Amplimexon 61 IMiDs 61 EXPAREL TM 61 selective androgen receptor modulator 61 Insegia 61 ocrelizumab 61 Octreolin 61 proteasome inhibitor 61 BLP# Liposome Vaccine 61 Genasense ® 61 Pimavanserin 61 favorable pharmacokinetic profile 61 Valortim 61 plus dexamethasone 61 GVAX 61 HDAC Inhibitor 61 castration resistant prostate cancer 61 estramustine 61 KNS # 61 carboplatin paclitaxel 61 VELCADE melphalan 61 RGB # 61 INC# 61 receptor tyrosine kinase inhibitor 61 vosaroxin 61 paclitaxel Taxol 61 seliciclib CYC# 61 rALLy clinical trial 61 angiogenesis inhibitor 61 nonclinical studies 61 standard chemotherapy regimen 61 targeting CD# 61 TNFerade 61 OncoVEX 61 investigational drug 61 PEG PAL 61 apremilast 61 histone deacetylase inhibitor 61 cobiprostone 61 deforolimus 61 randomized Phase IIb 61 pharmacokinetic PK study 61 AZILECT ® 61 Allovectin 7 ® 61 TOLAMBA 61 CTAP# Capsules 61 Tarvacin TM 61 Campath alemtuzumab 61 refractory multiple myeloma 61 Dapagliflozin 61 SinuNase TM 61 NVA# 61 6R BH4 61 targeted radiotherapeutic 61 Locteron ® 61 Degarelix 61 RhuDex ® 61 IMC A# 60 Advexin 60 dasatinib Sprycel ® 60 Restanza 60 TO AVOID PREGNANCY WHILE 60 beta 1a 60 AQ4N 60 ofatumumab 60 Dalbavancin 60 superficial bladder cancer 60 DDP# 60 DXL# 60 palifosfamide 60 glucokinase activator 60 davunetide intranasal AL 60 reslizumab 60 GALNS 60 ELND# 60 Palifosfamide 60 PHX# 60 Ozarelix 60 Augment Injectable 60 Catena ® 60 MT# MEDI 60 LUVENIQ 60 StemEx 60 CCR5 antagonist 60 milatuzumab 60 placebo controlled Phase III 60 PROVENGE ® 60 FOLFOX4 60 leukemia AML 60 tamibarotene 60 bicifadine 60 PrevOnco 60 Viprinex 60 OHR/AVR# 60 prostate cancer CRPC 60 Maribavir 60 AzaSite Plus 60 heavily pretreated 60 systemically administered 60 LT NS# 60 Cethrin 60 ularitide 60 Behcet uveitis 60 AAG geldanamycin analog 60 ACAPODENE TM 60 daclizumab 60 elagolix 60 Pirfenidone 60 APOPTONE 60 Ophena 60 ACAPODENE 60 Perforomist ™ Inhalation Solution 60 ENMD # 60 rALLy trial 60 atrasentan 60 Cloretazine 60 squalamine 60 topical formulation 60 metastatic HRPC 60 REG1 60 Evoltra ® 60 INCB# [003] 60 EchoCRT 60 Fibrin Pad 60 icatibant 60 Phase III clinical trials 60 adecatumumab MT# 60 PROVENGE sipuleucel T 60 subcutaneously administered 60 epigenetic therapies 60 ProLindac 60 omacetaxine 60 Trofex 60 histone deacetylase HDAC inhibitor 60 EndoTAG TM -1 60 Vandetanib 60 AEGR 60 Androxal TM 60 Presents Preclinical 60 immunomodulatory therapy 60 JAK1 60 MEK inhibitor RDEA# 60 omiganan 60 XL# XL# XL# 60 carfilzomib 60 Taxotere ® 60 Belinostat 60 Amigal 60 Pertuzumab 60 ToGA 60 Ranolazine 60 Phase 1a clinical 60 temsirolimus 60 somatostatin analogue 60 Azedra TM 60 ruxolitinib 60 Aclidinium 60 FOLFOX6 chemotherapy regimen 60 DAVANAT 60 PEGylated Fab fragment 60 PROCHYMAL 60 TASQ 60 DAVANAT R 60 Teriflunomide 60 forodesine hydrochloride 60 faropenem 60 docetaxel Taxotere 60 Memryte 60 satraplatin Phase 60 lapatinib Tykerb 60 ALN VSP 60 MKC# MKC# PP 60 Phase III HEAT 60 Phase IIIb 60 BR.# 60 tasocitinib 60 BZL# 60 MYDICAR 60 INT# [002] 60 cannabinor 60 Xeloda ® 60 polymerase inhibitor 60 Arimoclomol 60 huN# DM1 60 MDV# 60 otelixizumab 60 visilizumab 60 oral anticoagulant 60 pan histone deacetylase 60 JZP 60 Abiraterone acetate 60 RRMS patients 60 Nuvion 60 budesonide foam 60 MGCD# [002] 60 PEGylated anti 60 XL# SAR# 60 Civacir 60 INSPIRE Trial Phase III 60 Alpharadin 60 Clevudine 60 NATRECOR R 60 GATTEX ® 60 Omnitarg 60 successfully commercialize Iluvien 60 Combination REOLYSIN R 60 Pemetrexed 60 PSMA ADC 60 Fibrillex TM 60 JAK inhibitors 60 Dabigatran etexilate 60 Torisel 60 investigational hepatitis C 60 generation Hsp# inhibitor 60 CUSTOM III 60 viral kinetic 60 BARACLUDE R 60 Litx 60 IDX# 60 orally administered inhibitor 60 Ketotransdel 60 PROSTVAC VF 60 Pegasys ® 60 TACI Ig 60 ONCONASE 60 RSD# 60 ibandronate 60 UPLYSO 60 relapsing MS 60 HspE7 60 Rotigotine 60 PREOS 60 DR Cysteamine 60 AVE# 60 REOLYSIN ® 60 cetuximab Erbitux ® 60 ACZ# 60 MoxDuo IR 60 methylnaltrexone 60 tafamidis 60 urocortin 2 60 nucleoside analog 60 #D#C# 60 randomized Phase 60 Myelodysplastic Syndrome MDS 60 Indaflex TM 60 Phase 2a Clinical Trial 60 GW# [003] 60 Nexavar sorafenib 60 Ofatumumab 60 Clolar 60 BARACLUDE ® 60 investigational therapies 60 Vicriviroc 60 docetaxel chemotherapy 60 Doxil ® 60 plus prednisone 60 FTY# 60 2 methoxyestradiol 60 Phase Ib IIa 60 Arikace 60 NP2 Enkephalin 60 Cetrorelix 60 Aryplase 60 febuxostat 60 TKM ApoB 60 Phase Ib clinical trials 60 intranasal formulation 60 ADAGIO study 60 prostate cancer mCRPC 60 #I TM# 60 S/GSK# 59 ZD# [001] 59 PF # [001] 59 GLPG# 59 pancreatic neuroendocrine tumors 59 LBH# 59 Revimmune 59 valopicitabine 59 YONDELIS R 59 phase IIIb 59 CYT# QbG# 59 CINQUIL 59 Onconase 59 DACH platinum 59 Vilazodone 59 HCV protease inhibitor 59 T Pred 59 octreotide acetate 59 FOLFIRI 59 Aplidin 59 Angiocept 59 IMPACT IMmunotherapy 59 dose escalation 59 Triapine 59 LCP Tacro 59 tigecycline 59 non nucleoside inhibitor 59 lomitapide 59 velafermin 59 antiepileptic drug 59 Hepatocellular Carcinoma HCC 59 AVN# [001] 59 MACUGEN 59 Phase IIb 59 Prostate AdenoCarcinoma Treatment 59 Phase IIa 59 Xinlay 59 novel histone deacetylase 59 sunitinib 59 CB2 selective receptor agonist 59 darinaparsin 59 anidulafungin 59 TREANDA 59 ASA# 59 Keppra ® 59 Gliadel Wafer 59 TYZEKA 59 Pazopanib 59 Quinamed 59 tivozanib 59 LEP ETU 59 imatinib resistant 59 bortezomib Velcade R 59 dalbavancin 59 PRECiSE 59 low dose cytarabine 59 itraconazole 59 Forodesine HCl 59 Fodosine 59 Cardio Vascu Grow 59 leucovorin 59 R sorafenib tablets 59 iroxanadine 59 tocilizumab 59 Cimzia ® certolizumab pegol 59 BrachySil TM 59 Phase IIa trials 59 StemEx R 59 Granulocyte Colony Stimulating Factor 59 infusional 5-FU/LV 59 olaparib 59 DermaVir Patch 59 HP Acthar Gel repository 59 Initiates Phase II 59 Excellarate 59 gastrointestinal stromal tumors GIST 59 refractory APL 59 MEK inhibitor 59 medullary thyroid cancer 59 NLX P# 59 inhaled formulation 59 Jevtana 59 Onalta ™ 59 cetuximab Erbitux R 59 telaprevir VX 59 XL# XL# 59 dose cohorts 59 dopamine partial agonist 59 Gabapentin GR 59 phase III isavuconazole 59 Telatinib 59 BCR ABL inhibitor 59 Thiarabine 59 noninfectious uveitis 59 Bevacizumab 59 MGCD# [001] 59 TroVax ® 59 bosutinib 59 voclosporin 59 CG# [003] 59 relapsed MM 59 PROSTVAC ® 59 platelet inhibitor 59 SUTENT 59 TRO# 59 oral rivaroxaban 59 canakinumab 59 Anavex #-# 59 ® natalizumab 59 mipomersen 59 ATL/TV# 59 Telavancin 59 pharmacodynamic PD 59 SNT MC# 59 drug ISA# 59 aflibercept VEGF Trap 59 Complete Response 59 Cleviprex TM clevidipine 59 anticancer agent 59 Zysolin TM 59 MNTX 59 arzoxifene 59 Menerba 59 lenalidomide dexamethasone 59 Phase 2a Study 59 octreotide 59 androgen independent 59 Phase III pivotal 59 hoFH 59 NXL# 59 pazopanib 59 panitumumab 59 Elesclomol 59 hematological cancers 59 Zavesca R 59 GVAX ® 59 systemic immunosuppressive drugs 59 Lung Rx 59 delafloxacin 59 ALGRX 59 Xyrem ® 59 galiximab 59 octreotide implant 59 crofelemer 59 ATL# [001] 59 Ridaforolimus 59 SCCHN 59 oxypurinol 59 Perifosine 59 radezolid 59 ciclesonide 59 ALN TTR 59 refractory AML 59 Combidex 59 SERMs 59 Isolagen Therapy 59 Phase III Clinical Trial 59 rindopepimut 59 oral taxane 59 NEVO ™ 59 Albuferon 59 refractory CLL 59 pain palliation 59 TRISENOX 59 recurrent NSCLC 59 leading oral taxane 59 Naproxcinod 59 Intravenous CP 59 Dyloject TM 59 ANYARA 59 multicenter Phase III 59 abiraterone acetate 59 hepatitis C protease inhibitor 59 SUCCEED trial 59 Fampridine SR 59 investigational immunotherapy 59 NPSP# 59 Ceflatonin R 59 ritonavir boosted 59 Ganite ® 59 AMEVIVE 59 resminostat 59 ancrod 59 Adalimumab 59 torezolid 59 Initiates Phase III 59 DOXIL 59 active comparator 59 antibody MAb 59 Corlux 59 tolevamer 59 Dual Opioid 59 oral antiviral 59 optimal dosing regimens 59 TNF alpha inhibitor 59 Epratuzumab 59 ZK EPO 59 Brentuximab Vedotin SGN 59 cintredekin besudotox 59 aclidinium bromide 59 TAXOTERE R 59 Zerenex ™ 59 tenofovir emtricitabine 59 Advaxis Phase 59 Omacetaxine 59 Exenatide 59 TNF Tumor Necrosis Factor 59 LUX Lung 59 FTY# fingolimod 59 vorinostat 59 topical NSAID 59 viral kinetics 59 lixisenatide 59 bevacizumab Avastin 59 Xcytrin R 59 alfa 2a 59 demonstrated antitumor activity 59 QLT# 59 Tovaxin 59 darinaparsin ZIO 59 Hsp# inhibitor 59 TG# [001] 59 TASKi2 59 dacetuzumab 59 Gemcitabine 59 SPIRIT FIRST 59 CLARITY study 59 SUTENT ® 59 paliperidone ER 59 OMS#HP 59 schizophrenia CIAS 59 Xerecept 59 tosedostat 59 dextofisopam 59 relapsed SCLC 59 PFO migraine 59 DCVax ® Brain 59 ADVANCE PD 59 rFIXFc 59 Safinamide 59 retinal vein occlusion induced 59 herpetic keratitis 59 thetreatment 59 severe hypercholesterolemia 59 Factor VIIa 59 ALK inhibitor 59 BIBW 59 diabetic macular edema DME 59 Boceprevir 59 Phase III randomized controlled 59 ALN PCS 59 bardoxolone 59 OMAPRO 59 rasagiline tablets 59 abatacept Orencia 59 HCV SPRINT 59 RAPAFLO 59 adalimumab Humira 59 imatinib Gleevec ® 59 IMC #B 59 bazedoxifene 59 azacitidine 59 Anturol 59 Blinatumomab

Back to home page